49608-01-7

Usage

Uses

Used in Pharmaceutical Industry:
Ethyl 6-chloronicotinate is used as a key intermediate in the preparation of potent H3 receptor antagonists. These antagonists have potential applications in the treatment of various disorders, such as insomnia, cognitive impairment, and allergies, by modulating the histamine H3 receptor.
Used in Organic Synthesis:
Ethyl 6-chloronicotinate is used as a starting material in the synthesis of ethyl 5-[5-(1H-benzimidazol-2-yl)pyridin-2-yl]ethynylpyridine-2-carboxylate. Ethyl 6-chloronicotinate is prepared by reacting Ethyl 6-chloronicotinate with 2-[6-(ethynyl)pyridin-3-yl]-1H-benzimidazole under microwave irradiation. The resulting product has potential applications in various fields, such as medicinal chemistry and materials science, due to its unique structure and properties.

Upstream product

• 5326-23-8 6-Chloro-3-pyridinecarboxylic acid 
• 64-17-5 ethanol 
• 14906-63-9 1-oxy-nicotinic acid ethyl ester 
• 2398-81-4 Nicotinic acid N-oxide 
• 78-39-7 Triethyl orthoacetate 
• 58757-38-3 6-Chloronicotinoyl chloride 

Downstream Products

• 427886-41-7 Ethyl 6-(3,4,5-trimethoxyphenyl)nicotinate 
• 135883-37-3 ethyl 6-(4-tert butylphenyl)-ethynyl nicotinate 
• 1187189-63-4 ethyl 6-(4-bromo-3-formylphenoxy)nicotinate 
• 5326-23-8 6-Chloro-3-pyridinecarboxylic acid 
• 1417792-23-4 C₃₂H₂₈ClFN₄O₉S 
• 1417792-45-0 C₁₇H₁₇ClN₂O₅S 
• 1417792-49-4 C₃₅H₃₄ClFN₄O₉S 
• 224817-12-3 6-chloronicotinic acid benzylamide 
• 7151-91-9 2-methylthio-5-pyridinecarboxamide 
• 78210-60-3 6-ethylpyridine-3-carboxamide 
• 29051-44-3 6-phenylpyridine-3-carboxylic acid 

Relevant academic research and scientific papers

Discovery of a new class of JMJD6 inhibitors and structure–activity relationship study

JmjC domain-containing protein 6 (JMJD6) has been thought as a potential target for various diseases particularly cancer. However, few selective JMJD6 inhibitors have been reported. In this investigation, molecular docking and biological activity evaluation were performed to retrieve new JMJD6 inhibitors, which led to the identification of a hit compound, J2. Further structural optimization and structure–activity relationship (SAR) analysis towards J2 were carried out, which gave a new potent JMJD6 inhibitor, 7p. This compound showed an IC50 value of 0.681 μM against JMJD6, but displayed no activity against other tested JmjC domain-containing protein family members, indicating good selectivity (>100 fold). Collectively, this investigation offers a selective JMJD6 inhibitor, which could be taken as a lead compound for subsequent drug discovery targeting JMJD6.

2-(1H-pyrazol-3-yl) pyridine derivative as well as preparation method and application thereof

The invention belongs to the field of medicinal chemistry, particularly relates to a compound shown in a formula I, or a stereoisomer, salt, prodrug or solvate thereof, and also relates to a preparation method of the compound and application of the compound in preparation of drugs for treating related diseases mediated by histone demethylase JMJD6.

INHIBITORS OF HEPATITIS C VIRUS POLYMERASE

The present invention provides, among other things, compounds represented by the general Formula I: (I) and pharmaceutically acceptable salts thereof, wherein L and A (and further substituents) are as defined in classes and subclasses herein and compositions (e.g., pharmaceutical compositions) comprising such compounds, which compounds are useful as inhibitors of hepatitis C virus polymerase, and thus are useful, for example, as medicaments for the treatment of HCV infection.

NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS AND BENAMIDE COMPOUNDS AND DRUGS CONTAINING THE SAME

Disclosed are compounds represented by formula (I) which have triglyceride biosynthesis inhibitory activity in the liver and inhibitory activity against the secretion of apolipoprotein B-containing lipoprotein from the liver and particularly have excellent inhibitory activity against the secretion of apolipoprotein B-containing lipoprotein, are free from side effect of accumulation of lipids in the liver, and are useful for the treatment and prevention of hyperlipidemia and arteriosclerotic diseases. In formula (I), R1 and R2 represent alkyl, alkoxy, cycloalkyl, phenyl, alkenyl, alkynyl, or a five- or six-membered saturated or unsaturated heterocyclic ring, or R1 and R2, together with a nitrogen atom to which R1 and R2 are attached, may form a ring; R3 and R4 represent a hydrogen atom, alkyl, a halogen atom, hydroxyl, nitrile, alkoxycarbonyl, alkoxy, or carboxyl; or R2 and R3 may be attached to each other to form -(CH2)m-, -N=CH-, -CH=N-, or -(C1-6 alkyl)C=N-; A, D, E, and G each represent a carbon atom, or any one of A, D, E, and G represents a nitrogen atom with the other three each representing a carbon atom; Q represents a nitrogen atom or a carbon atom; Y represents a group represented by formula (II) wherein X represents a hydrogen atom, group -C(=O)N(R5)R6 or group -C(=O)OR7, R8 is absent or represents a bond, an oxygen atom, a sulfur atom, -SO2-, -SO-, -CH2-CH2-, or - CH=CH-, and R9 and R10 represent a hydrogen atom, alkyl, alkoxy, a halogen atom, or hydroxyl; and Z represents - (CH2)n-, -O-(CH2)i-, or -C(=O)NH-(CH2)i-.

Syntheses of substituted pyridines, quinolines and diazines via palladium-catalyzed cross-coupling of aryl Grignard reagents

The palladium-catalyzed cross-coupling reactions between arylmagnesium halides (phenylmagnesium chloride, mesitylmagnesium bromide, 4-(methoxycarbonyl)phenylmagnesium chloride and 4-cyanophenylmagnesium chloride) and halopyridines allowed the synthesis of substituted pyridines. Owing to the remarkably mild conditions used (often below 0°C), the reaction could be extended to the use of functionalized halopyridines, haloquinolines and halodiazines.

Disubstituted acetylenes bearing heterobicyclic groups and heteroaromatic or phenyl groups having retinoid like activity

Compounds of the formula where R1and R2, independently are alkyl groups having 2 to 8 carbons; R3is hydrogen or lower alkyl; X is S, O or N—R4where R4is hydrogen or lower alkyl; Y is phenyl or pyridyl

Method for preparing esters of halonicotinic acids

The present invention provides a method of preparation of ethyl 6-halonicotinate, wherein said halo is chloro or iodo, which comprises reacting the 6-halonicotinic acid with triethyl orthoacetate, to yield the ethyl-6-halonicotinate.

Preparation of substituted 2-chloropyridines

A process for the preparation of a substituted 2-chloropyridine derivatives of the formula STR1 in which R1, R2, R3 and R4 represent hydrogen or various other radicals, which comprises reacting a pyridine-1-oxide of the formula STR2 with an aromatic carbonyl chloride in the presence of an inert organic solvent and in the presence of an acid acceptor at a temperature between about -20° C. and 200° C.

2-(Alkylamino)nicotinic Acid and Analogs. Potent Angiotensin II Antagonists

A series of pyridines and other six-membered ring heterocycles connected to a biphenyltetrazole with a-CH2-NR'-link (1) were discovered to be potent angiotensin II antagonists.In the pyrimidine carboxylic acid series (W = CR, X = N, Y = CH, Z = COOH), compounds with an alkyl group (R') on the exocyclic nitrogen were much more potent than compounds with an alkyl group (R) on the heterocyclic ring.The corresponding pyridine, pyridazine, pyrazine, and 1,2,4-triazine carboxylic acids also showed potent in vitro angiotensin II antagonism.The pyridine (W, X, Y = CH, Z = COOH, R' = n-C3H7) demonstrated potent in vitro activity (pA2 = 10.10, rabbit aorta, and Ki = 0.61 nM, receptor binding in rat liver) as well as exceptional oral antihypertensive activity and bioavailability.Any nonacidic replacement for the carboxylic acid was detrimental for activity.

Angiotensin II receptor antagonists

Compounds are disclosed having the formula: STR1 The compounds of the invention are angiotensin II receptor antagonists.